Table 2.
Comparison of analgesic drug prescription between chronic non-cancer pain opioid substitution treatment (CNCP OST) patients group and CNCP control group.
| CNCP OST patients group | CNCP control group | P-value | |
|---|---|---|---|
| N = 8,499 | N = 1,989 | ||
| % (N) | % (N) | ||
| Opioid analgesic use | 47.8 (4,065) | 68.0 (1,352) | < 0.0001 |
| Strong opioids | 4.6 (394) | 8.5 (169) | < 0.0001 |
| Fentanyl | 0.6 (49) | 1.4 (28) | < 0.0001 |
| Morphine | 3.2 (273) | 5.2 (103) | < 0.0001 |
| Oxycodone | 1.3 (106) | 3.4 (67) | < 0.0001 |
| Weak opioids | 46.1 (3,921) | 65.4 (1,300) | < 0.0001 |
| Codeine | 19.0 (1,618) | 32.1 (638) | < 0.0001 |
| Tramadol | 28.3 (2,403) | 39.7 (790) | < 0.0001 |
| Opium | 13.0 (1107) | 21.4 (425) | < 0.0001 |
| Exclusive non-opioid analgesic use | 52.2 (4,434) | 32.0 (637) | < 0.0001 |
| NSAIDs | 35.8 (3,044) | 20.7 (412) | < 0.0001 |
| Paracetamol | 48.0 (4,073) | 29.1 (579) | < 0.0001 |
| Nefopam | 1.6 (132) | 0.4 (8) | < 0.0001 |
| Triptans | 8.1 (687) | 10.0 (200) | 0.004 |
CNCP, chronic non-cancer pain; OST, opioid substitution treatment; NSAIDs, non-steroidal anti-inflammatory drugs.